Search Results

Xilis and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to deploy Xilis’s proprietary MicroOrganoSphere™ (MOS) technology in support of preclinical research to accelerate the development of novel cancer therapies.

Xilis today announced the addition of four members to its newly formed Scientific Advisory Board (SAB).

Xilis, Inc. announced that it is participating in the recently announced public-private Oncode-PACT.

Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.

Xilis expands CAB to five members to help company develop its MicroOrganoSphere™ technology.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Xilis, Inc. announced today the presentation of data on the company’s proprietary MOS technology. Data were presented at the 2021 European Society for Medical Oncology (ESMO) Congress in an oral presentation and two poster presentations.

Xilis, Inc. today announced the close of a $70 million Series A financing.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system